Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 3

recruiting
3 974
countries
28
conditions
2 106

44 trials match your criteria

Chronic graft versus host disease

Not recruiting

Study on the Safety and Effectiveness of Ibrutinib for Children and Young Adults with Chronic Graft Versus Host Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ibrutinib

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing ACP-196 and Ibrutinib for Patients with High-Risk Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Diffuse large B-cell lymphoma+2

Not recruiting

Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Marginal zone lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib and Rituximab for Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Chronic lymphocytic leukaemia

Not recruiting

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Chronic lymphocytic leukaemia+1

Not recruiting

Study Comparing Ibrutinib and Venetoclax with Chlorambucil and Obinutuzumab for First-line Treatment in Patients with Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Mantle cell lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Mantle cell lymphoma refractory

Not recruiting

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.